Suzanne Carreira
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 90 publications
A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer.
Journal: Investigational new drugs
Published: February 04, 2026
Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers.
Journal: The Journal of clinical investigation
Published: July 23, 2025
An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate Cancer.
Journal: European urology oncology
Published: July 14, 2025
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes.
Journal: European urology oncology
Published: February 13, 2025
Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer.
Journal: iScience
Published: January 27, 2025
NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 29, 2024
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer.
Journal: Cancer cell
Published: April 12, 2024
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer.
Journal: Nature communications
Published: March 07, 2024
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 16, 2024
BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity.
Journal: The Journal of clinical investigation
Published: February 06, 2024
RNASEH2B loss and PARP inhibition in advanced prostate cancer.
Journal: The Journal of clinical investigation
Published: December 08, 2023
Last Updated: 09/26/2026